+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Compounded pimobendan for canine chronic degenerative mitral valve disease and pulmonary hypertension



Compounded pimobendan for canine chronic degenerative mitral valve disease and pulmonary hypertension



International Journal of Pharmaceutical Compounding 16(1): 34-41



Pimobendan (Vetmedin) is an effective treatment for canine chronic degenerative mitral valve disease and dilated cardiomyopathy. In an off-label use, it may also be of benefit for the treatment of pulmonary hypertension in dogs. In this report, we describe the effects of a palatable customized oral form of pimobendan used with both compounded and commercially manufactured conventional drug therapy to treat degenerative mitral valve disease and pulmonary hypertension in two small dogs. For those patients, who resisted many types of oral medication, the standard manufactured dose of pimobendan was inappropriate. Formulations of the preparations used to treat the patients described in this report are provided for easy reference. It should be noted that at the time of this writing, Boehringer Ingelheim GmbH (Ingelheim am Rhein, Germany), the manufacturer of pimobendan, has expressed concern about the stability of that agent in aqueous compounded form. To our knowledge, no current data confirming the stability or bioequivalence of compounded pimobendan exist.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052269295

Download citation: RISBibTeXText

PMID: 23050309


Related references

Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs. Journal of Veterinary Internal Medicine 23(6): 1190-1196, 2010

Pulmonary hypertension in canine degenerative mitral valve disease. Journal of Veterinary Cardiology 14(1): 149-164, 2012

Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease". Journal of Veterinary Internal Medicine 22(2): 243; Author Reply 245-243; Author Reply 245, 2008

Prognostic value of pulmonary hypertension in patients undergoing surgery for degenerative mitral valve disease with leaflet prolapse. Journal of Cardiac Surgery 27(6): 668-675, 2013

Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. Journal of Small Animal Practice 46(3): 121-130, 2005

Incidence, epidemiology, and prognosis of residual pulmonary hypertension after mitral valve repair for degenerative mitral regurgitation. American Journal of Cardiology 107(5): 755-760, 2011

Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. Journal of Veterinary Internal Medicine 21(4): 742-753, 2007

Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, randomized study. Journal of veterinary internal medicine- 21(4): 742-753, 2007

The Burden of Pulmonary Hypertension in Patients with Degenerative Mitral Valve Disease in Enugu South-East Nigeria: An Echocardiographic Based Study. Annals of Medical and Health Sciences Research 6(3): 172-175, 2016

Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001-2005). Journal of the American Veterinary Medical Association 229(11): 1772-1778, 2006

Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded and randomized study". Journal of Veterinary Internal Medicine 22(2): 243-4; Author Reply 245-6, 2008

The impact of preoperative and postoperative pulmonary hypertension on long-term surgical outcome after mitral valve repair for degenerative mitral regurgitation. Annals of Thoracic and Cardiovascular Surgery 21(1): 53-58, 2015

Echocardiographic assessment of canine degenerative mitral valve disease. Journal of Veterinary Cardiology 14(1): 127-148, 2012

Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study. Australian Veterinary Journal 94(9): 324-328, 2016